AR103064A1 - Compuestos moduladores de fxr (nr1h4) - Google Patents

Compuestos moduladores de fxr (nr1h4)

Info

Publication number
AR103064A1
AR103064A1 ARP150104131A ARP150104131A AR103064A1 AR 103064 A1 AR103064 A1 AR 103064A1 AR P150104131 A ARP150104131 A AR P150104131A AR P150104131 A ARP150104131 A AR P150104131A AR 103064 A1 AR103064 A1 AR 103064A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
group
halo
cycloalkyl
Prior art date
Application number
ARP150104131A
Other languages
English (en)
Inventor
Xu Jianjun
j watkins William
C Schmitt Aaron
e kropf Jeffrey
S Currie Kevin
A Blomgren Peter
Kremoser Claus
Kinzel Olaf
Gege Christian
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AR103064A1 publication Critical patent/AR103064A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Abstract

Compuestos que se unen al NR1H4 (FXR) y actúan como agonistas de FXR. Además, el uso de los compuestos para la preparación de un medicamento para el tratamiento de enfermedades y/o condiciones por unión de dichos compuestos a dicho receptor nuclear y un proceso para la síntesis de dichos compuestos. Reivindicación 1: Un compuesto caracterizado porque es de acuerdo con la fórmula (1), un enantiómero, diasterómero, tautómero, solvato, profármaco o sal farmacéuticamente aceptable del mismo, donde R se selecciona entre el grupo que consiste en hidrógeno, halógeno, C₁₋₆-alquilo, C₂₋₆-alquenilo, C₂₋₆-alquinilo, halo-C₁₋₆-alquilo, C₀₋₆-alquilen-R⁷, C₀₋₆-alquilen-O-R⁷, C₀₋₆-alquilen-CN, C₀₋₆-alquilen-NR⁷R⁸, O-C₃₋₁₀-cicloalquilo, O-C₁₋₆-alquilen-O-R⁷, O-C₃₋₁₀-heterocicloalquilo, C₀₋₆-alquilen-CO₂R⁷, C₀₋₆-alquilen-C(O)R⁷, C₀₋₆-alquilen-C(O)NR⁷R⁸, C₀₋₆-alquilen-C(O)NR⁷SO₂R⁷, C₀₋₆-alquilen-N(R⁷)C(O)R⁷, C₀₋₆-alquilen-SOˣ-R⁷, C₀₋₆-alquilen-SO₃H, C₀₋₆-alquilen-SO₂-NR⁷R⁸, C₀₋₆-alquilen-SO₂-NR⁸COR⁷, C₀₋₆-alquilen-N(R⁷)SO₂-R⁸, y C₀₋₆-alquilen-SO₂-C₃₋₁₀-heterocicloalquilo, donde alquileno, cicloalquilo, heterocicloalquilo y heteroarilo de 5 ó 6 miembros no están sustituidos o están sustituidos con 1 a 4 sustituyentes seleccionados en forma independiente entre el grupo que consiste en halógeno, CN, C₁₋₃-alquilo, halo-C₁₋₃-alquilo, OH, oxo, CO₂H, SO₃H, O-C₁₋₃-alquilo y O-halo-C₁₋₃-alquilo; R⁷ se selecciona en forma independiente entre el grupo que consiste en hidrógeno, C₁₋₆-alquilo, halo-C₁₋₆-alquilo, C₀₋₆-alquilen-C₃₋₈-cicloalquilo, C₀₋₆-alquilen-C₃₋₈-heterocicloalquilo, heteroarilo de 5 ó 6 miembros y fenilo, donde alquilo, alquileno, cicloalquilo, heterocicloalquilo, fenilo y heteroarilo no están sustituidos o están sustituidos con 1 a 6 sustituyentes seleccionados en forma independiente entre el grupo que consiste en halógeno, CN, OH, oxo, CO₂H, C₁₋₃-alquilo, halo-C₁₋₃-alquilo, O-C₁₋₃-alquilo, O-halo-C₁₋₃-alquilo, SO₃H y SO₂-C₁₋₃-alquilo; R⁸ se selecciona en forma independiente entre el grupo que consiste en hidrógeno, C₁₋₆-alquilo, halo-C₁₋₆-alquilo y C₃₋₆-cicloalquilo; o R⁷ y R⁸ cuando se toman junto con el nitrógeno al cual están unidos pueden formar un anillo de 3 a 8 miembros que contiene átomos de carbono y que contiene opcionalmente 1 ó 2 heteroátomos seleccionados entre O, S o N, donde el anillo no está sustituido o está sustituido con 1 a 4 sustituyentes seleccionados en forma independiente entre el grupo que consiste en fluoro, OH, oxo, C₁₋₄-alquilo y halo-C₁₋₄-alquilo; A es un arilo monocíclico o bicíclico de 6 - 10 miembros o un heteroarilo monocíclico o bicíclico de 5 - 10 miembros que contiene 1 a 5 heteroátomos seleccionados en forma independiente entre el grupo que consiste en N, O y S, donde arilo y heteroarilo no están sustituidos o están sustituidos con uno o dos grupos seleccionados en forma independiente entre el grupo que consiste en OH, halógeno, CN, O-C₁₋₆-alquilo, O-halo-C₁₋₆-alquilo, C₁₋₆-alquilo, halo-C₁₋₆-alquilo, C₃₋₆-cicloalquilo y halo-C₃₋₆-cicloalquilo; B es un anillo C₅₋₈-cicloalquilo o, si Y es N, entonces es B un C₄₋₈-heterocicloalquilo o C₄₋₈-heterocicloalquilo en puente que contiene un átomo de nitrógeno, y donde el sustituyente Q no es directamente adyacente al sustituyente A; Q se selecciona entre el grupo que consiste en fenilo, piridilo, tiazolilo, tiofenilo, pirimidilo, oxazolilo, pirazolilo, imidazolilo y triazolilo, cada uno no sustituido o sustituido con uno o dos grupos seleccionados en forma independiente entre el grupo que consiste en halógeno; C₁₋₄-alquilo, halo-C₁₋₄-alquilo, C₁₋₄-alcoxi o halo-C₁₋₄-alcoxi; Y se selecciona entre N, CH o CF; Z se selecciona entre el grupo de fórmulas (2), donde L se selecciona entre el grupo que consiste en una unión, C₁₋₃-alquileno y C₁₋₃-alquilen-O-; Y se selecciona entre fenilo, piridilo, N-óxido de piridilo, pirimidilo, piridinonilo, pirimidinonilo, C₄₋₈-cicloalquilo, y C₄₋₈-heterocicloalquilo, donde fenilo, piridilo, N-óxido de piridilo, pirimidilo, piridinonilo, pirimidinonilo, C₄₋₈-cicloalquilo y C₄₋₈-heterocicloalquilo están sustituidos con R² y R³ y opcionalmente sustituidos una o dos veces con un grupo seleccionado entre fluoro, cloro, CN, NH₂, NH(C₁₋₃-alquilo), N(C₁₋₃-alquil)₂, C₁₋₃-alquilo, fluoro-C₁₋₃-alquilo, OH, C₁₋₃-alcoxi, fluoro-C₁₋₃-alcoxi, C₃₋₆-cicloalquilo y fluoro-C₃₋₆-cicloalquilo; R¹ se selecciona entre el grupo que consiste en C₁₋₄-alquilo y C₃₋₆-cicloalquilo, donde C₁₋₄-alquilo no está sustituido o está, sustituido con 1 a 3 sustituyentes seleccionados en forma independiente entre el grupo que consiste en fluoro, hidroxi, C₁₋₃-alcoxi y fluoro-C₁₋₃-alcoxi, y C₃₋₆-cicloalquilo no está sustituido o está sustituido con 1 a 3 sustituyentes seleccionados en forma independiente entre el grupo que consiste en fluoro, hidroxi, C₁₋₃-alquilo, fluoro-C₁₋₃-alquilo, C₁₋₃-alcoxi y fluoro-C₁₋₃-alcoxi; R² y R³ se seleccionan en forma independiente entre el grupo que consiste en hidrógeno, halógeno, C₁₋₃-alquilo, halo-C₁₋₃-alquilo, C₁₋₃-alcoxi, halo-C₁₋₃-alcoxi, ciclopropilo y fluoro-ciclopropilo; R⁴ se selecciona en forma independiente entre halógeno, C₁₋₃-alquilo, halo-C₁₋₃-alquilo, C₁₋₃-alcoxi, halo-C₁₋₃-alcoxi, C₃₋₆-cicloalquilo, y fluoro-C₃₋₆-cicloalquilo; R⁵ se selecciona entre el grupo que consiste en hidrógeno, fluoro, CH₃, CHF₂ y CF₃; n se selecciona entre 0, 1, 2, 3 y 4; y x se selecciona entre 0, 1 y 2.
ARP150104131A 2014-12-17 2015-12-17 Compuestos moduladores de fxr (nr1h4) AR103064A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14004260.7A EP3034499A1 (en) 2014-12-17 2014-12-17 Novel FXR (NR1H4) modulating compounds

Publications (1)

Publication Number Publication Date
AR103064A1 true AR103064A1 (es) 2017-04-12

Family

ID=52338777

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150104131A AR103064A1 (es) 2014-12-17 2015-12-17 Compuestos moduladores de fxr (nr1h4)

Country Status (23)

Country Link
US (1) US9938278B2 (es)
EP (2) EP3034499A1 (es)
JP (2) JP6452821B2 (es)
KR (1) KR101955840B1 (es)
CN (1) CN107108595B (es)
AR (1) AR103064A1 (es)
AU (1) AU2015365945B2 (es)
BR (1) BR102015031497A2 (es)
CA (1) CA2971241C (es)
EA (1) EA033642B1 (es)
ES (1) ES2719902T3 (es)
HK (1) HK1245786B (es)
IL (1) IL252496A0 (es)
MX (1) MX2017007522A (es)
NZ (1) NZ732210A (es)
PL (1) PL3233831T3 (es)
PT (1) PT3233831T (es)
SG (1) SG11201704539TA (es)
SI (1) SI3233831T1 (es)
TR (1) TR201906401T4 (es)
TW (1) TWI598345B (es)
UY (1) UY36452A (es)
WO (1) WO2016096116A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP3034499A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
PT3277286T (pt) 2015-03-31 2021-07-01 Enanta Pharm Inc Derivados de ácidos biliares como agonistas de fxr/tgr5 e métodos de utilização destes
WO2017128896A1 (zh) * 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
CN106995416A (zh) * 2016-01-26 2017-08-01 上海翰森生物医药科技有限公司 Fxr激动剂及其制备方法和应用
US10080741B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
EP3468962A1 (en) 2016-06-13 2019-04-17 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
WO2018067704A1 (en) 2016-10-04 2018-04-12 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
WO2018081285A1 (en) 2016-10-26 2018-05-03 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
CN106588804B (zh) * 2016-12-09 2018-11-09 都创(上海)医药科技有限公司 一种作为类法尼醇x受体(fxr)的化合物的制备方法
WO2018133730A1 (zh) * 2017-01-20 2018-07-26 四川科伦博泰生物医药股份有限公司 一种杂环化合物及其制备方法和用途
SI3600309T1 (sl) 2017-03-28 2022-10-28 Gilead Sciences, Inc. Terapevtske kombinacije za zdravljenje bolezni jeter
RS62711B1 (sr) 2017-04-12 2022-01-31 Il Dong Pharma Derivati izoksazola kao agonisti nuklearnih receptora i njihova upotreba
WO2018215070A1 (en) * 2017-05-24 2018-11-29 Johann Wolfgang Goethe-Universität Frankfurt am Main Dual modulators of farnesoid x receptor and soluble epoxide hydrolase
AU2018360575A1 (en) * 2017-11-01 2020-06-18 Bristol-Myers Squibb Company Alkene spirocyclic compounds as farnesoid X receptor modulators
TW201922737A (zh) 2017-11-01 2019-06-16 美商必治妥美雅史谷比公司 作為法尼醇x受體調節劑之螺環化合物
WO2019089670A1 (en) * 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Alkene compounds as farnesoid x receptor modulators
US11370785B2 (en) 2017-11-01 2022-06-28 Bristol-Myers Squibb Company Multicyclic compounds as farnesoid X receptor modulators
SG11202003827YA (en) 2017-11-01 2020-05-28 Bristol Myers Squibb Co Bridged bicyclic compounds as farnesoid x receptor modulators
CA3082191C (en) 2017-12-07 2021-09-21 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US10689391B2 (en) 2017-12-12 2020-06-23 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
WO2019120088A1 (zh) * 2017-12-22 2019-06-27 四川科伦博泰生物医药股份有限公司 异噁唑衍生物及其制备方法和用途
CN108129348B (zh) * 2018-01-12 2019-11-01 南开大学 叠氮三氟甲氧基化合物及其合成方法
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019160813A1 (en) 2018-02-14 2019-08-22 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
CN110818704B (zh) * 2018-08-08 2023-08-01 广州市恒诺康医药科技有限公司 螺桥环化合物、其药物组合物及其用途
CN112638473B (zh) * 2018-08-08 2022-06-07 因奥必治疗有限公司 用于调节类法尼醇x受体的化合物以及制备和使用所述化合物的方法
JP7314946B2 (ja) 2018-08-31 2023-07-26 ソニーグループ株式会社 照明装置、および表示装置
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
KR20210114457A (ko) 2019-01-15 2021-09-23 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
AR118050A1 (es) 2019-02-15 2021-09-15 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
KR20210129128A (ko) 2019-02-19 2021-10-27 길리애드 사이언시즈, 인코포레이티드 Fxr 효능제의 고체 형태
CN110144349A (zh) * 2019-04-21 2019-08-20 吉林省农业科学院 一种大豆叶特异启动子GmNR1(Glyma14g33480)及其分离方法和应用
US11555032B2 (en) 2019-05-13 2023-01-17 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
TW202114672A (zh) 2019-07-23 2021-04-16 瑞士商諾華公司 使用fxr促效劑的肝臟疾病之組合治療
US20220265614A1 (en) 2019-07-23 2022-08-25 Novartis Ag Treatment comprising fxr agonists
JP2022547452A (ja) 2019-09-03 2022-11-14 ノバルティス アーゲー Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療
JP2022548617A (ja) 2019-09-19 2022-11-21 ノバルティス アーゲー Ｆｘｒアゴニストを含む処置
CN114502198A (zh) 2019-09-30 2022-05-13 诺华股份有限公司 包括使用fxr激动剂的治疗
AU2020408067B2 (en) 2019-12-20 2024-03-28 Novartis Ag Combination treatment of liver diseases using integrin inhibitors
EP4090327A1 (en) 2020-01-15 2022-11-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of fxr agonists for treating an infection by hepatitis d virus
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
KR20230154806A (ko) 2021-01-14 2023-11-09 엔요 파마 Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
WO2023016521A1 (zh) * 2021-08-12 2023-02-16 上海赛默罗生物科技有限公司 取代***类衍生物、其制备方法、药物组合物和用途
CN113876789B (zh) * 2021-10-28 2022-05-20 兰州大学第一医院 Licraside用于制备治疗胆汁淤积药物的用途
CN117430574B (zh) * 2023-12-20 2024-03-22 潍坊医学院 一种苯并呋喃衍生物及其制备方法、用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532729A (ja) 1998-12-23 2002-10-02 グラクソ グループ リミテッド 核内受容体のリガンドのアッセイ
DE60131967D1 (de) 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US20050107475A1 (en) 2002-03-21 2005-05-19 Jones Stacey A. Methods of using farnesoid x receptor (frx) agonists
US7319109B2 (en) 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
US20070166710A1 (en) 2003-03-31 2007-07-19 Markus Stoffel Methods for inhibiting adipogenesis and for treating type 2 diabetes
ATE526318T1 (de) 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
US7863302B2 (en) 2006-02-03 2011-01-04 Eli Lilly And Company Compounds and methods for modulating FX-receptors
DK2029547T3 (da) 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
US8106077B2 (en) 2006-05-24 2012-01-31 Eli Lilly And Company Compounds and methods for modulating FXR
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
US7998995B2 (en) * 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
JP2010529996A (ja) 2007-06-13 2010-09-02 グラクソスミスクライン エルエルシー ファルネソイドｘ受容体アゴニスト
CN101877966A (zh) 2007-07-02 2010-11-03 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CN101952286A (zh) * 2007-12-21 2011-01-19 阿斯利康(瑞典)有限公司 用于治疗和雄激素受体有关的病症的双环衍生物
EP2289883A1 (en) * 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP2655369A1 (en) 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
CN103370315A (zh) 2010-12-20 2013-10-23 Irm责任有限公司 用于调控法尼醇x受体的组合物和方法
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2545964A1 (en) * 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
EP3034499A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
MA41252A (fr) * 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1

Also Published As

Publication number Publication date
TW201627292A (zh) 2016-08-01
HK1245786B (zh) 2019-11-08
EP3233831A1 (en) 2017-10-25
KR101955840B1 (ko) 2019-03-07
NZ732210A (en) 2018-11-30
EA033642B1 (ru) 2019-11-12
JP6452821B2 (ja) 2019-01-16
ES2719902T3 (es) 2019-07-16
UY36452A (es) 2016-07-29
TR201906401T4 (tr) 2019-05-21
SI3233831T1 (sl) 2019-05-31
CA2971241A1 (en) 2016-06-23
AU2015365945A1 (en) 2017-06-15
KR20170093969A (ko) 2017-08-16
PT3233831T (pt) 2019-05-09
PL3233831T3 (pl) 2019-08-30
TWI598345B (zh) 2017-09-11
EP3034499A1 (en) 2016-06-22
JP2018162309A (ja) 2018-10-18
US20170298068A1 (en) 2017-10-19
MX2017007522A (es) 2017-08-22
AU2015365945B2 (en) 2018-09-27
BR102015031497A2 (pt) 2016-06-21
EA201791002A1 (ru) 2018-06-29
WO2016096116A1 (en) 2016-06-23
SG11201704539TA (en) 2017-07-28
EP3233831B1 (en) 2019-02-20
US9938278B2 (en) 2018-04-10
JP2018500305A (ja) 2018-01-11
CN107108595B (zh) 2021-04-06
CA2971241C (en) 2021-06-22
IL252496A0 (en) 2017-07-31
CN107108595A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
PH12016501935A1 (en) Inhibitors of cyclin-dependent kinase 7 (cdk7)
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR106948A1 (es) Agonistas del receptor de apelina y método de uso
AR108011A1 (es) Moduladores receptores de estrógenos
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR095885A1 (es) Compuestos derivados de arilpirrolopiridina como inhibidores de lrrk2
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR087127A1 (es) Compuestos que se unen a fxr (nr1h4) y modulan su actividad
AR110789A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
AR110790A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
AR115296A1 (es) Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
AR099498A1 (es) Compuestos de triazina y su uso farmacéutico
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
AR117544A1 (es) Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer
AR109296A1 (es) Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat)
EA201791816A1 (ru) Ингибиторы kv1.3 и их применение в медицине
AR098522A1 (es) Compuesto de triazolo-piridina
AR110282A1 (es) Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR109650A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2

Legal Events

Date Code Title Description
FB Suspension of granting procedure